What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Tirzepatide, Semaglutide, Retatrutide, Cagrilintide and related GLP-1 / GIP / GCG receptor agonists for metabolic and weight-management research.
GIP / GLP-1 dual receptor agonist
GIP / GLP-1 / glucagon tri-agonist
GLP-1 receptor agonist
Long-acting amylin analog
Nicotinamide adenine dinucleotide
Reference-code fill; Retatrutide identity verified per batch COA · 30 mg
Reference-code fill; Retatrutide identity verified per batch COA · 5 mg
Reference-code fill; Semaglutide identity verified per batch COA · 30 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 10 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 30 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 60 mg
GLP-1 receptor agonist (long-acting)
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
GLP-1 / glucagon dual receptor agonist (BI 456906)
NNMT inhibitor (5-Amino-1-methylquinolinium iodide)
AMPK pathway activator · exercise mimetic research compound
Fatty-acid-transport nutrient
Pan-ERR agonist · exercise mimetic compound
19-mer
Prohibitin-targeting adipose vascular peptide
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Buyer types across this category
Documentation available for this class
Sold as a bulk active for research and for compounding-pharmacy formulation in jurisdictions where local regulations permit. Not a finished dosage form and not labeled for direct human administration as shipped. The GLP-1 class is on active regulatory watchlists in several major markets, buyers are responsible for verifying current scheduling and compounding eligibility for the destination at the time of dispense.
